Voyager Therapeutics reported a third-quarter 2026 net loss of $24.7 million, narrowing from $27.9 million in the prior-year period, driven by lower research and development expenses of $24.4 million compared to $35.9 million. Collaboration revenue declined to $4.0 million from $13.4 million as activities transitioned beyond the research phase. The company ended Q3 with $132.1 million in cash and marketable securities, extending its operating runway into the second quarter of 2028. Clinically, VY7523 PET imaging data is expected in Q4 2026, while VY1706 dosing is pending enrollment. Voyager Therapeutics is a biotechnology company dedicated to leveraging genetics to treat neurological diseases.
